- Published on
KembaraXtra-Medicine – Mitral Valve Prolapse
Mitral valve prolapse (MVP) is characterized by bulging of one or both mitral valve leaflets into the left atrium during systole due to incomplete coaptation of the valve leaflets. It is most commonly caused by myxomatous degeneration of the valve, involving proliferation of the spongiosa layer with disruption of the fibrosa layer, along with excessive stretching of the chordae tendineae that places traction on the papillary muscles. Mitral regurgitation (MR) may develop in some patients. MVP typically presents between 10 and 16 years of age and is more common in females than males. It is generally benign in young women, whereas men over 50 years of age are more likely to develop severe regurgitation and require surgical intervention. MVP has a strong hereditary component and may be inherited in an autosomal dominant pattern with variable penetrance. A range of neuroendocrine and autonomic disturbances may also be associated with the condition.
MVP is associated with several connective tissue and systemic disorders, including Marfan syndrome, Ehlers–Danlos syndrome, osteogenesis imperfecta, pseudoxanthoma elasticum, Stickler syndrome, systemic lupus erythematosus, polyarteritis nodosa, polycystic kidney disease, von Willebrand disease, and Duchenne muscular dystrophy. These conditions contribute to abnormal connective tissue structure, predisposing the mitral valve to prolapse.
Clinical manifestations can be grouped into symptoms related to autonomic dysfunction, symptoms resulting from progression of mitral regurgitation, and complications such as stroke, infective endocarditis, or arrhythmias. Palpitations occur in up to 40% of patients and are commonly due to premature ventricular beats or paroxysmal supraventricular tachycardia. Chest pain occurs in about 10% of patients and is typically sharp, localized, nonexertional, and of variable duration. Dysautonomia-related symptoms include anxiety, panic attacks, fatigue, depression, migraine headaches, irritable bowel symptoms, and orthostatic intolerance. Syncope or presyncope is uncommon, occurring in less than 1% of cases, while dyspnea and fatigue are generally infrequent unless significant MR is present.
Physical examination classically reveals a mid-to-late systolic click best heard at the cardiac apex, often followed by a late systolic murmur. Maneuvers that reduce left ventricular volume, such as standing or Valsalva, cause the click to occur earlier in systole, while squatting delays it. Many patients exhibit skeletal abnormalities, including an asthenic body habitus, increased arm span relative to height, scoliosis or kyphosis, pectus excavatum, arachnodactyly, joint hypermobility, hypomastia, and a high-arched (“cathedral”) palate.
Diagnosis is often made clinically based on history and auscultation, with echocardiography used to confirm uncertain cases. On echocardiography, classic MVP is defined by superior displacement of the mitral leaflets greater than 2 mm into the left atrium during systole with leaflet thickness of at least 5 mm, while nonclassic MVP shows similar displacement with thinner leaflets. Electrocardiography is usually normal but may show ST-T wave changes, premature atrial or ventricular contractions, or QT prolongation. Chest radiography is typically normal unless significant MR leads to left atrial or ventricular enlargement.
Management is generally conservative, as many patients are asymptomatic and do not require treatment. β-blockers may be used for troublesome palpitations or chest pain, while magnesium supplementation may alleviate symptoms related to classic MVP syndrome. Orthostatic symptoms may respond to increased salt intake or fludrocortisone. Antiplatelet therapy is indicated in patients with transient ischemic attack or stroke. Significant MR, particularly in the presence of hypertension, may benefit from ACE inhibitors. Antibiotic prophylaxis is recommended only for selected patients with MVP and MR undergoing high-risk procedures, and is not indicated for isolated clicks without MR.
Hospital admission is reserved for patients with severe mitral regurgitation, ischemic chest pain, syncope, life-threatening arrhythmias, or cerebrovascular events. Asymptomatic patients without significant MR or dysrhythmias can be safely discharged. Cardiology referral is warranted for ventricular arrhythmias, evidence of disease progression, or risk of sudden death, while cardiothoracic surgical evaluation is indicated for symptomatic severe MR, reduced ejection fraction, pulmonary hypertension, or atrial fibrillation. Valve repair is preferred over replacement when feasible.
Regular follow-up every 3–5 years is recommended to monitor for progression of disease. Patients with MVP and MR should receive appropriate endocarditis prophylaxis during at-risk procedures and undergo evaluation before participating in high-intensity sports. A key clinical pitfall is attributing symptoms such as chest pain or syncope solely to MVP without appropriate evaluation, as MVP remains a recognized cause of sudden death in athletes.
Mitral valve prolapse (MVP) is characterized by bulging of one or both mitral valve leaflets into the left atrium during systole due to incomplete coaptation of the valve leaflets. It is most commonly caused by myxomatous degeneration of the valve, involving proliferation of the spongiosa layer with disruption of the fibrosa layer, along with excessive stretching of the chordae tendineae that places traction on the papillary muscles. Mitral regurgitation (MR) may develop in some patients. MVP typically presents between 10 and 16 years of age and is more common in females than males. It is generally benign in young women, whereas men over 50 years of age are more likely to develop severe regurgitation and require surgical intervention. MVP has a strong hereditary component and may be inherited in an autosomal dominant pattern with variable penetrance. A range of neuroendocrine and autonomic disturbances may also be associated with the condition.
MVP is associated with several connective tissue and systemic disorders, including Marfan syndrome, Ehlers–Danlos syndrome, osteogenesis imperfecta, pseudoxanthoma elasticum, Stickler syndrome, systemic lupus erythematosus, polyarteritis nodosa, polycystic kidney disease, von Willebrand disease, and Duchenne muscular dystrophy. These conditions contribute to abnormal connective tissue structure, predisposing the mitral valve to prolapse.
Clinical manifestations can be grouped into symptoms related to autonomic dysfunction, symptoms resulting from progression of mitral regurgitation, and complications such as stroke, infective endocarditis, or arrhythmias. Palpitations occur in up to 40% of patients and are commonly due to premature ventricular beats or paroxysmal supraventricular tachycardia. Chest pain occurs in about 10% of patients and is typically sharp, localized, nonexertional, and of variable duration. Dysautonomia-related symptoms include anxiety, panic attacks, fatigue, depression, migraine headaches, irritable bowel symptoms, and orthostatic intolerance. Syncope or presyncope is uncommon, occurring in less than 1% of cases, while dyspnea and fatigue are generally infrequent unless significant MR is present.
Physical examination classically reveals a mid-to-late systolic click best heard at the cardiac apex, often followed by a late systolic murmur. Maneuvers that reduce left ventricular volume, such as standing or Valsalva, cause the click to occur earlier in systole, while squatting delays it. Many patients exhibit skeletal abnormalities, including an asthenic body habitus, increased arm span relative to height, scoliosis or kyphosis, pectus excavatum, arachnodactyly, joint hypermobility, hypomastia, and a high-arched (“cathedral”) palate.
Diagnosis is often made clinically based on history and auscultation, with echocardiography used to confirm uncertain cases. On echocardiography, classic MVP is defined by superior displacement of the mitral leaflets greater than 2 mm into the left atrium during systole with leaflet thickness of at least 5 mm, while nonclassic MVP shows similar displacement with thinner leaflets. Electrocardiography is usually normal but may show ST-T wave changes, premature atrial or ventricular contractions, or QT prolongation. Chest radiography is typically normal unless significant MR leads to left atrial or ventricular enlargement.
Management is generally conservative, as many patients are asymptomatic and do not require treatment. β-blockers may be used for troublesome palpitations or chest pain, while magnesium supplementation may alleviate symptoms related to classic MVP syndrome. Orthostatic symptoms may respond to increased salt intake or fludrocortisone. Antiplatelet therapy is indicated in patients with transient ischemic attack or stroke. Significant MR, particularly in the presence of hypertension, may benefit from ACE inhibitors. Antibiotic prophylaxis is recommended only for selected patients with MVP and MR undergoing high-risk procedures, and is not indicated for isolated clicks without MR.
Hospital admission is reserved for patients with severe mitral regurgitation, ischemic chest pain, syncope, life-threatening arrhythmias, or cerebrovascular events. Asymptomatic patients without significant MR or dysrhythmias can be safely discharged. Cardiology referral is warranted for ventricular arrhythmias, evidence of disease progression, or risk of sudden death, while cardiothoracic surgical evaluation is indicated for symptomatic severe MR, reduced ejection fraction, pulmonary hypertension, or atrial fibrillation. Valve repair is preferred over replacement when feasible.
Regular follow-up every 3–5 years is recommended to monitor for progression of disease. Patients with MVP and MR should receive appropriate endocarditis prophylaxis during at-risk procedures and undergo evaluation before participating in high-intensity sports. A key clinical pitfall is attributing symptoms such as chest pain or syncope solely to MVP without appropriate evaluation, as MVP remains a recognized cause of sudden death in athletes.
0 Comments
